Lawrence Brozowski

Just trying to make enough money to retire and live happily ever after.

[Lawrence Brozowski @vision_quest61]

If you love coloring, check out https://t.co/qqMlEBsRe7: AI-generated coloring pages, photo-to-lineart, color online, and one-click multi-page coloring books. Free daily credits! https://t.co/VoPM9lTdo9

[Lawrence Brozowski @vision_quest61]

Just found https://t.co/qqMlEBsRe7 — a free AI coloring page generator. Turn any text or photo into a printable coloring page, no watermark and free daily credits. Give it a try! https://t.co/VoPM9lTdo9

[Lawrence Brozowski @vision_quest61]

@cappinkirksport @tigers The manager should be fired. LOLOL. He's in first place.

[Lawrence Brozowski @vision_quest61]

@MattNachtrab @GovRonDeSantis @JaneCastor @USRepKCastor My prayer's are with you and your family. Stay safe.

[ATAT @teslatesla111]

@MattNachtrab @elonmusk @elonmusk

[Matt Nachtrab @MattNachtrab]

@elonmusk , we could use your help with a company that has a phase 3 #Alzheimers treatment that has experienced the most evil short seller attack I have been able to find. The families in in the trial are speaking out saying their family members are improving on the drug and they want to keep taking it while the FDA waits to approve. You do not improve on Alzheimer's... its a one way horrifying path into the darkness of dementia. The drug is safe with no known side effects... NONE. Over 1m doses have been administered across the 1500+ patients that took it in the trials.

The shorts have successfully isolated the company and suffocated the stock down to <$500m

The 100 or so patients have fallen off open label access to the drug and about 400 more by the end of the year. Imagine how they feel after watching their husband, wife, mother, father, or grandparent improve or stabilize the last 12 months only to lose them to the darkness of Alzheimer's after the drug is not available. This is a direct result to short seller and competitor attacks

The company is Cassava Sciences, $sava
The Drug is #simufilam

The first phase 3 trial completes in October and they report data in November or December. The Government and the shorts are doing one last attempt to stop the trials by indicting the head scientist and squeezing the company BEFORE the phase 3 read out. I argue its because they know it will be impossible to indict them after the drug is shown effective.

I have started a patient advocacy group to help get them access to the drug. If you are an open label extended patient losing access to the drug please join our group here: https://t.co/d72OgFPtGV

The scientist being squeezed by the government in this attack is Dr. Wang. To help in his defense against the DOJ go here: https://t.co/D8KuVJmOl3

Here are some tweets from me with much more background about what is happening. This has been a 3 year battle against these people. :

Article about the company: https://t.co/mDiDdjXueE

How the competitive and short seller attack is taking away the drug from patients. This has been their goal the whole time... stop the safe drug from a phase 3 trial:
https://t.co/spNHRqR32R

Vile short seller attack shaming a rape victim:
https://t.co/EVVDEpM56B

[Vinnie @Vinnie66007649]

Ps remind @SenSanders about Simufilam, a most promising safe 💊 in 2 FDA AD trials. DSMB had 2 safety audits &amp; recommend trials to proceed.

Gangs of shorter are pushing agencies to stop the trials. Rethink w/ 797 pts is only 4 months for completion.

@US_FDA @DOJCrimDiv

[Lawrence Brozowski @vision_quest61]

@georgelageX @German_in_Ohio @MattNachtrab @lexfridman Fourth.

[Lawrence Brozowski @vision_quest61]

@MattNachtrab Want to confirm what is written. You put, "The FDA is not going to pause or halt $sava trials". Below you put, "So are they are going to halt a drug with about 2000 people...because the DOJ weighed in?". Did you confirmation that Cassava spoke to the FDA or your opinion?

[Matt Nachtrab @MattNachtrab]

The FDA cleared the Clinical Trial Sites for the Open Label Trial of simufilam from $sava $savaw.

I reviewed all of the trial sites listed for the Open Label locations (1). I compared the principal investigators at each site to investigators that had investigations by the FDA (2).

At least IMIC was investigated specifically for their FDA trial of Cassava as a result of the @qcmfunds and others short and distort campaign against $sava. As you can see in the image attached, they were investigated, and no action was taken. The investigation was completed 12/21/22.

Two other sites (Neuro-Behavioral Clinical Research and out of Ohio and Ottawa Memory Clinic) were investigated by the FDA later, and no actions were taken. I have not gotten confirmation that either of these sites were investigated specifically for their Cassava trials. Regardless, ZERO investigators involved the Open Label trials of Cassava received Citations by the FDA despite the infiltration by the short sellers (@qcmfunds sent FAKE trial participants to at least 2 clinical trial sites and have been reported to the FDA criminal investigation divisions for trial interference. See image and report (4))

Personally, I think this is big news as the market clearly does not believe the incredible simufilam Open Label data that held Alzheimer's cognition to zero change in mild patients for 18 months. Serious FUD was spread about the trial by short sellers. The FDA not only clear the CP, but they also investigated at least one open label trial site and cleared them. The SEC and DOJ are sitting on their hands, but the most important government body, the FDA, stands behind the Cassava trials.

The ultimate test for simufilam is the phase 3 data in the very large phase 3 trial for Alzheimer's disease (~2000 patients). The first trial named RETHINK is about 800 patients for 12 months will read out Q4 2024 or Q1 2025. Typically phase 3 trials for AD receive a market cap of 21 billion (3) or ~$500 per share for $sava. How much will $sava close that gap before Q4 of 2024 as the market sees this trial has a high chance of success?

(1) Open Label and CMS for simufilam - https://t.co/4KfTDPUXMn
(2) Inspections section of the FDA Data Dashboard - https://t.co/VJLkB4xS9a
(3) Assessing How Much an Alzheimer’s Drug is Worth- https://t.co/7Gu3ecm4Qd
(4) https://t.co/bF5NXpGUq2

[Vinnie @Vinnie66007649]

Hope ⁦@DOJCrimDiv⁩ also looks into shorting of small biotech co.

$SAVA has been under attack since CP scandal ⁦@US_FDA⁩. The SP has been manipulated w/ option.

Shorts don’t want a safe promising AD drug to succeed.

⁦@ChrisPrentice⁩ https://t.co/u1V9G56yGQ

[Simon Erickson @7Innovator]

What are your thoughts about Cassava Sciences $SAVA?

Its proposed drug Simufilam (in Phase 3) is a pill that would proactively prevent the amyloid protein buildups that lead to Alzheimer's.

That sounds innovative...but also very hard to do.

What should I know about $SAVA?

[AD3 𝕏 @AD3ENDALZ]

$SAVA YELLOW SQUARE 🟨 AND YELLOW TRIANGLE STILL BETTER THAN ANYTHING ELSE OUT THERE
OVER 18 months !!! 💜🙏🏻
#ENDALZ

@JoeSpringer

[Archisaurus YMB @Archisaurus_YMB]

I projected @CassavaSciences’ latest 12-Month OL and 6-Month CMS trial results for their safe/effective drug #Simufilam onto assumed accurate (now modified by me) chart circulating.

IMPORTANT: Unlike other drugs shown, $SAVA trials INCLUDE MODERATE (not just mild) #ALZ PATIENTS.

[Lawrence Brozowski @vision_quest61]

@TruthfulHand @CassavaSciences Great news!

[AD3 𝕏 @AD3ENDALZ]

#ENDALZ 💜 $SAVA
THIS NEEDS TO BE EXPEDITED TO PATIENTS IN NEED ASAP @FDACDERDirector @US_FDA @FDASpox

[Lawrence Brozowski @vision_quest61]

Accept my invite to score 3 free swag! https://t.co/L2q0hxewBJ

[Lawrence Brozowski @vision_quest61]

Accept my invite to score 3 free swag! https://t.co/ktfXfJzAqy

[Joe Springer @JoeSpringer]

$SAVA in Cancer

[Lawrence Brozowski @vision_quest61]

@SenGillibrand @braun4indiana Please review Simufilam from Cassava Sciences. It's in Phase 3 trials and shows to reverse Alzheimer's. It has been hit by false claims. Many families are speaking out about Simufilam and saying it is helping their loved ones.